Corcept Therapeutic announced that it has initiated CATALYST, a 1,000-patient, Phase 4 trial examining the prevalence of hypercortisolism in patients with difficult to control type 2 diabetes. Those patients with hypercortisolism will be offered entry into a randomized, double-blind, placebo-controlled study of Korlym. "We are excited that our CATALYST trial is now open," said Bill Guyer, PharmD, Corcept’s Chief Development Officer. "Many smaller studies conducted over the last fifteen years have found that the prevalence of hypercortisolism in patients with type 2 diabetes is substantially higher than in the general population. The most prominent diabetologists in the United States helped us design and are participating in CATALYST, which will be the largest study of its kind ever to be conducted. Data from CATALYST will enable physicians to better identify and care for these patients. We expect to complete enrollment by the end of this year."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CORT:
- Corcept Therapeutics Initiates CATALYST Clinical Trial
- Corcept Therapeutics price target lowered to $32 from $33 at Canaccord
- Corcept Therapeutics commences tender offer to purchase 7.5M shares
- Corcept Therapeutics sees FY23 revenue $430M- $450M, consensus $434.79M
- Corcept Therapeutics reports Q4 EPS 14c, consensus 22c